Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer
Top Cited Papers
Open Access
- 3 February 2014
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (11), 4233-4238
- https://doi.org/10.1073/pnas.1321937111
Abstract
Thyroid cancer is a common endocrine malignancy that encompasses well-differentiated as well as dedifferentiated cancer types. The latter tumors have high mortality and lack effective therapies. Using a paired-end RNA-sequencing approach, we report the discovery of rearrangements involving the anaplastic lymphoma kinase (ALK) gene in thyroid cancer. The most common of these involves a fusion between ALK and the striatin (STRN) gene, which is the result of a complex rearrangement involving the short arm of chromosome 2. STRN-ALK leads to constitutive activation of ALK kinase via dimerization mediated by the coiled-coil domain of STRN and to a kinase-dependent, thyroid-stimulating hormone–independent proliferation of thyroid cells. Moreover, expression of STRN-ALK transforms cells in vitro and induces tumor formation in nude mice. The kinase activity of STRN-ALK and the ALK-induced cell growth can be blocked by the ALK inhibitors crizotinib and TAE684. In addition to well-differentiated papillary cancer, STRN-ALK was found with a higher prevalence in poorly differentiated and anaplastic thyroid cancers, and it did not overlap with other known driver mutations in these tumors. Our data demonstrate that STRN-ALK fusion occurs in a subset of patients with highly aggressive types of thyroid cancer and provide initial evidence suggesting that it may represent a therapeutic target for these patients. Significance Thyroid cancer is common and has an excellent outcome in many cases, although a proportion of these tumors have a progressive clinical course and high mortality. Using whole-transcriptome (RNA-sequencing) analysis, we discovered previously unknown genetic events, anaplastic lymphoma kinase (ALK) gene fusions, in thyroid cancer and demonstrate that they occur more often in aggressive cancers. The most common fusion identified in these tumors involved the striatin (STRN) gene, and we show that it is transforming and tumorigenic in vivo. Finally, we demonstrate that the kinase activity of STRN-ALK can be blocked by ALK inhibitors, raising a possibility that ALK fusions may be used as a therapeutic target for patients with the most aggressive and frequently lethal forms of thyroid cancer.Keywords
This publication has 35 references indexed in Scilit:
- Molecular pathogenesis and mechanisms of thyroid cancerNature Reviews Cancer, 2013
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK InhibitorsClinical Cancer Research, 2011
- Molecular genetics and diagnosis of thyroid cancerNature Reviews Endocrinology, 2011
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase InhibitorsCancer Research, 2011
- Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK GeneCancer Research, 2011
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 2011
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer DevelopmentCell, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcriptsGenome Biology, 2009